Company: XAIR
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001641172-25-023243
Chunk: 64

Company: Beyond Air, Inc.
Filing Date: 2025-08-12
Form: 10-Q
Item: Part I, Item 1
Chunk 64
---
 successful in obtaining
an adequate level of financing for the development and commercialization of our other product candidates.

There
are numerous risks and uncertainties associated with the development of our NO delivery system and we are unable to estimate the amounts
of increased capital outlays and operating expenses associated with the completion of the research and development of our product candidates.

32

Our
future capital requirements will depend on many factors, including:

    ●
    the
    progress and costs of our preclinical studies, clinical trials and other research and development activities;
  
    ●
    the
    costs of commercializing the LungFit® system;
  
    ●
    the
    scope, prioritization and number of our clinical trials and other research and development programs;
  
    ●
    the
    costs and timing of obtaining certification or regulatory approval for our product candidates;
  
    ●
    the
    costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights;
  
    ●
    the
    costs of, and timing for, strengthening our manufacturing agreements for production of sufficient clinical quantities of our product
    candidates;
  
    ●
    the
    potential costs of contracting with third parties to provide marketing and distribution services for us or for building such capacities
    internally;
  
    ●
    the
    costs of acquiring or undertaking the development and commercialization efforts for additional, future therapeutic applications of
    our product candidates;
  
    ●
    the
    magnitude of our general and administrative expenses; and
  
    ●
    any
    cost that we may incur under current and future in-and-out-licensing arrangements relating to our product candidates.

ITEM
3. Quantitative and Qualitative Disclosures About Market Risk

We
are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial
position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of foreign currency
exchange rates.

ITEM
4. Controls and Procedures

Evaluation
of Disclosure Controls and Procedures

We
carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer
(our principal executive officer) and Chief Financial Officer (our principal financial officer), of the effectiveness of the design and
operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Disclosure controls
and